Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

키워드

참고문헌 (87)

1. Sharpe HR, "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world", Immunology, 160, pp.223~232 (2020)
2. Chakraborty C, "SARS-CoV-2 causing pneumoniaassociated respiratory disorder(COVID-19) : diagnostic and proposed therapeutic options", Eur Rev Med Pharmacol Sci, 24, pp.4016~4026 (2020)
3. Liu K, "Clinical features of COVID-19 in elderly patients : a comparison with young and middle-aged patients", J Infect, 80, pp.e14~e18 (2020)
4. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
5. Lythgoe MP, "Ongoing clinical trials for the management of the COVID-19 pandemic", Trends Pharmacol Sci, 41, pp.363~382 (2020)
6. Chen W, "Promise and challenges in the development of COVID-19 vaccines", Hum Vaccin Immunother, 16, pp.2604~2608 (2020)
7. Lurie N, "Developing COVID-19 vaccines at pandemic speed", N Engl J Med, 382, pp.1969~1973 (2020)
8. Peeples L, "News feature : avoiding pitfalls in the pursuit of a COVID-19 vaccine", Proc Natl Acad Sci U S A, 117, pp.8218~8221 (2020)
9. Heaton PM, "The COVID-19 vaccine-development multiverse", N Engl J Med, 383, pp.1986~1988 (2020)
10. Martin JE, "A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial", Vaccine, 26, pp.6338~6343 (2008)
11. Folegatti PM, "Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine : a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial", Lancet Infect Dis, 20, pp.816~826 (2020)
12. Fuller DH, "Amplifying RNA vaccine development", N Engl J Med, 382, pp.2469~2471 (2020)
13. Yi C, "mRNA vaccines : possible tools to combat SARS-COV-2", Virol Sin, 35, pp.259~262 (2020)
14. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
15. Chen WH, "The SARS-CoV-2 vaccine pipeline : an overview", Curr Trop Med Rep, pp.1~4 (2020)
16. Cao Z, "Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients", Virol J, 7, pp.299~ (2010)
17. Hotez PJ, "COVID-19 vaccine design : the Janus face of immune enhancement", Nat Rev Immunol, 20, pp.347~348 (2020)
18. Du L, "Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model", Vaccine, 25, pp.2832~2838 (2007)
19. De Groot AS, "Clinical applications of immunomics", pp.39~69 (2009), Springer
20. Bhattacharya M, "Development of epitope-based peptide vaccine against novel coronavirus 2019(SARS-CoV-2) : immunoinformatics approach", J Med Virol, 92, pp.618~631 (2020)
21. Bhattacharya M, "A SARS-CoV-2 vaccine candidate : in-silico cloning and validation", Inform Med Unlocked, 20, pp.100394~ (2020)
22. Giurgea LT, "Universal coronavirus vaccines : the time to start is now", NPJ Vaccines, 5, pp.43~ (2020)
23. Yuan M, "A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV", Science, 368, pp.630~633 (2020)
24. Tian X, "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody", Emerg Microbes Infect, 9, pp.382~385 (2020)
25. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
26. Lan J, "Structure of the SARSCoV-2 spike receptor-binding domain bound to the ACE2 receptor", Nature, 581, pp.215~220 (2020)
27. Wang C, "A human monoclonal antibody blocking SARS-CoV-2 infection", Nat Commun, 11, pp.1~6 (2020)
28. Ella KM, "Coronavirus vaccine : light at the end of the tunnel", Indian Pediatr, 57, pp.407~410 (2020)
29. Melgaço JG, "Protective immunity after COVID-19 has been questioned : what can we do without SARS-CoV-2-IgG detection", Cell Immunol, 353, pp.104114~ (2020)
30. Priyanka, "Protective immunity against COVID-19 : Unravelling the evidences for humoral vs. cellular components", Travel Med Infect Dis, 39, pp.101911~ (2020)
31. Casanova JL, "A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection", Cell, 181, pp.1194~1199 (2020)
32. Manners C, "Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines", Cureus, 12, pp.e8399~ (2020)
33. Yang J, "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", Nature, 586, pp.572~577 (2020)
34. Bakker WA, "Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV", Vaccine, 29, pp.7188~7196 (2011)
35. Gao Q, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369, pp.77~81 (2020)
36. Risson E, "Inactivated vaccine for SARS-CoV-2", Nat Rev Immunol, 20, pp.353~ (2020)
37. Lazar M, "Characterisation of measles after the introduction of the combined measles-mumps-rubella(MMR)vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania", Euro Surveill, 24, pp.1900041~ (2019)
38. Grenga L, "Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines", Emerg Microbes Infect, 9, pp.1712~1721 (2020)
39. Jiang S, "Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome", Expert Rev Vaccines, 11, pp.1405~1413 (2012)
40. Moyle PM, "Modern subunit vaccines : development, components, and research opportunities", ChemMedChem, 8, pp.360~376 (2013)
41. Flood A, "Development of a freeze-dried, heat-stable influenza subunit vaccine formulation", PLoS One, 11, pp.e0164692~ (2016)
42. Kalita P, "Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2", Microb Pathog, 145, pp.104236~ (2020)
43. Shang W, "The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines", NPJ Vaccines, 5, pp.18~ (2020)
44. Qi X, "Construction and immunogenic studies of a mFc fusion receptor binding domain(RBD)of spike protein as a subunit vaccine against SARS-CoV-2 infection", Chem Commun(Camb), 56, pp.8683~8686 (2020)
45. Deering RP, "Nucleic acid vaccines : prospects for non-viral delivery of mRNA vaccines", Expert Opin Drug Deliv, 11, pp.885~899 (2014)
46. Saha RP, "Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19", Front Pharmacol, 11, pp.1258~ (2020)
47. Smith TR, "Immunogenicity of a DNA vaccine candidate for COVID-19", Nat Commun, 11, pp.2601~ (2020)
48. Yu J, "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", Science, 369, pp.806~811 (2020)
49. Walker SN, "SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients", J Clin Microbiol, 58, pp.e01533~20 (2020)
50. Kaur SP, "COVID-19 Vaccine : a comprehensive status report", Virus Res, 288, pp.198114~ (2020)
51. Amanat F, "SARS-CoV-2 vaccines : Status report", Immunity, 52, pp.583~589 (2020)
52. Corbett KS, "Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates", N Engl J Med, 383, pp.1544~1555 (2020)
53. Anderson EJ, "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults", N Engl J Med, 383, pp.2427~2438 (2020)
54. Mulligan MJ, "Phase I", II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, pp.586, 589~593
55. Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
56. Koch T, "Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome : an open-label, phase 1 trial", Lancet Infect Dis, 20, pp.827~838 (2020)
57. Lei C, "Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig", Nat Commun, 11, pp.2070~ (2020)
58. Kim E, "Microneedle array delivered recombinant coronavirus vaccines : immunogenicity and rapid translational development", EBioMedicine, 55, pp.102743~ (2020)
59. Deangelis CD, "Clinical trial registration : a statement from the international committee of medical journal editors", Arch Dermatol, 141, pp.76~77 (2005)
60. Nascimento IP, "Recombinant vaccines and the development of new vaccine strategies", Braz J Med Biol Res, 45, pp.1102~1111 (2012)
61. Funk CD, "A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic", Front Pharmacol, 11, pp.937~ (2020)
62. Li W, "Peptide vaccine: progress and challenges", Vaccines(Basel), 2, pp.515~536 (2014)
63. Grgacic EV, "Virus-like particles : passport to immune recognition", Methods, 40, pp.60~65 (2006)
64. Rohovie MJ, "Virus-like particles : next-generation nanoparticles for targeted therapeutic delivery", Bioeng Transl Med, 2, pp.43~57 (2017)
65. Mullard A, "COVID-19 vaccine development pipeline gears up", Lancet, 395, pp.1751~1752 (2020)
66. Saeidnia S, "From in vitro experiments to in vivo and clinical studies; pros and cons", Curr Drug Discov Technol, 12, pp.218~224 (2015)
67. Raimondi MT, "Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19", Theranostics, 10, pp.7034~7052 (2020)
68. Cohen J, "Vaccine designers take first shots at COVID-19", Science, 368, pp.14~16 (2020)
69. Kim YC, "COVID-19 vaccines : breaking record times to first-in-human trials", NPJ Vaccines, 5, pp.34~ (2020)
70. Escobar LE, "BCG vaccine protection from severe coronavirus disease 2019(COVID-19)", Proc Natl Acad Sci U S A, 117, pp.17720~17726 (2020)
71. Prasanta Raghab Mohapatra, "BCG vaccination induced protection from COVID-19", Indian Journal of Tuberculosis, 68(1), pp.119~124 (2021), Elsevier BV[DOI]
72. Banday AH, "Potential repurposed therapeutics and new vaccines against COVID-19and their clinical status", SLAS Discov, 25, pp.1097~1107 (2020)
73. Mahase E, "COVID-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows", BMJ, 371, pp.m4471~ (2020)
74. Elie Dolgin, "COVID-19 vaccines poised for launch, but impact on pandemic unclear", Nature Biotechnology (2020), Springer Science and Business Media LLC[DOI]
75. Thanh Le T, "The COVID-19vaccine development landscape", Nat Rev Drug Discov, 19, pp.305~306 (2020)
76. Bar-Zeev N, "Encouraging results from phase 1", 2 COVID-19 vaccine trials, 2020, pp.396, 448~449
77. Zhu FC, "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine : a doseescalation, open-label, non-randomised, first-in-human trial", Lancet, 395, pp.1845~1854 (2020)
78. Zhu FC, "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 396, pp.479~488 (2020)
79. Martin C, "mRNA vaccines : intellectual property landscape", Nat Rev Drug Discov, 19, pp.578~ (2020)
80. van Doremalen N, "ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2pneumonia in rhesus macaques", Nature, 586, pp.578~582 (2020)
81. Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
82. Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2020, pp.6736, 32466~32461
83. Chakraborty C, "India's cost-effective COVID-19 vaccine development initiatives", Vaccine, 38, pp.7883~7884 (2020)
84. Bregu M, "Accelerating vaccine development and deployment : report of a Royal Society satellite meeting", Philos Trans R Soc Lond B Biol Sci, 366, pp.2841~2849 (2011)
85. Gouglas D, "Estimating the cost of vaccine development against epidemic infectious diseases : a cost minimisation study", Lancet Glob Health, 6, pp.e1386~e1396 (2018)
86. Chakraborty C, "Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak", Arch Med Res, 51, pp.728~730 (2020)
87. Corey L, "A strategic approach to COVID-19 vaccine R&D", Science, 368, pp.948~950 (2020)

관련 논문AI추천